Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Would the presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
Would you offer SBRT for primary pulmonary adenoid cystic carcinoma in a patient who was medically not a surgical candidate?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?